CannaTech 2017 - The Future of Medicine: Genetics Based Personalized Treatment - Dr. David Meiri
Published on Apr 19, 2017
Dr. David "Dedi" Meiri from the Cancer Research lab at the Technion in Israel (aka "Dedi's Lab") takes us through a fascinating presentation on the identification of the effects of different Cannabis extracts on the proliferation and cell death of various cancer cell lines (and classification) according to genetic profile.
1. I think this is a very interesting and relevant presentation that takes a few replays to understand because I am not a scientist or Doctor. However, notice Dr. Meiri is looking for a specific cannabinoid to combat the illness based on the research he started 2 years ago.
2. They are now able to take an extract and identify the cannabinoids and 20 different strains that can be prescribed to the patient. Dr. Mieri mentions that each strain is a different medicine. There is a specifity between what is in the cannabis and what is affecting the cells being treated.
3. 96 different treatments are being analyzed by Israeli researchers and it is very important that the right type of cannabis is used to combat different illnesses due to the different effectiveness of each strain of cannabinoids. There is at least 144 different cannabinoids .
4. They are noticing that there is variability in the effectiveness of different cannabis types grown in different greenhouses at different times.
Connections to BLDV
Notice at 5:50 in the June 1, 2017 interview how the BLDV CEO refers to grow operations being set up in Florida and how they are high tech. The CEO explains that in the MMJ industry they are more concerned with the exact complement of cannabinoids in the plant. Josh indicates it is more of a recipe relying on genetics and monitoring of controllable factors within controlled spaces.
BLDV's environmental control knowledge through their work with Zeno Controls and Verve Living Systems gave them the position to understand the total environment of the space. Josh indicates that in the MMJ industry, it is important to bring technology to different areas. Connect the dots!
I think as pharmaceutical companies introduce different cannabis extracts and doctors start prescribing different MMJ targeted to treat specific illnesses, they will require reliable cultivators that can control grow and environmental factors to ensure the right cannabinoids are provided in the right MMJ strain as part of a secure and safe MMJ supply on a consistent basis.
Hence, this is why I think BLDV's approach to partner with Israeli firms to secure multiple opportunities to bring Medical Cannabis products and technology to North America where AMS will implement the correct high tech cultivation methods as part of the integrated facility approach is timely and full of foresight of the future MMJ market. See further information provided in previous two posts:
Eltron Research & Development was founded in 1982 and is a leading R&D organization with over 3 decades of experience providing technology solutions to industry. Our excellent track record of creating commercial-ready technologies has produced 3 spin-off companies and 77 patents, of which 29 have been licensed to industry.
Eltron’s staff consists of approximately 50 scientists and engineers (Ph.D, MS and BS level) who work in our state-of-the-art research facility in Boulder, Colorado. Eltron’s core strengths are applied chemistry and engineering in the following technology areas:
• Energy and Fuels: Clean and sustainable energy, novel biofuels synthesis, fuel reforming, gasification and sequestration
• Catalysts: Design, synthesis, evaluation and scale-up of heterogeneous and homogeneous, supported and unsupported materials
• Advanced Materials: Polymers, membranes, multifunctional composites, ceramics, novel paints and coatings, chemical energy storage systems, materials molding and nanotubes
• Chemicals & Chemical Processing: Ambient and high temperature chemical processes as well as electrochemical methodologies
• Environmental: Green electrolytic water treatment technology, contaminant remediation and sensor technology platforms
Eltron’s clients come from both private and public sectors. Eltron has completed more than 200 projects over 3 decades for many government agencies including the DOE, DOD,NASA, EPA, NIH and NSF.
The goal of Eltron’s business model is to commercialize as many of its technologies as possible via licensing Eltron technologies, developing Eltron technologies internally or with a partner, performing Contract R&D Services, and creating spin-off companies when appropriate(Eltron Water Systems, Continental Technologies, The BioCompactor Company).
Owner and President, Paul Grimmer, acquired Eltron R&D in 2005 and brings more than 30 years of experience in the petroleum industry.
Prior to Eltron, Mr. Grimmer spent 28years working atConoco primarily in upstream as an engineer, project manager, and then in business development. As President of Conoco’s Gas Solutions, he grew the “gas solutions” business within the company from its inception into a program that generated$100,000,000 annually, with a staff of more than240 people.
While focused on Fischer-Tropsch Gas-To-Liquids processes (GTL), Mr. Grimmer’s team developed several improvements and built a 400 barrel-per-day demonstration plant. This plant is the largestGTL plant in theWestern Hemisphere and the third largestGTL plant in theworld.
Since 2005, Mr. Grimmer has lead a major change within Eltron R&D: to broaden its focus from research to include technology development in an effort to begin to monetize the company’s collection of proprietary technologies.
News 
Market Data 
Discover 
